SCHEMBL468761

SCHEMBL468761

CC(=O)NCCS(=O)(=O)O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.56
MAPK1 P28482 1/20 0.56
HIF1A Q16665 1/20 0.56
PAOX Q6QHF9 3/20 0.46
TSHR P16473 1/20 0.46
ADRA1A P35348 1/20 0.45
ALDH1A1 P00352 1/20 0.44
LOX P28300 1/20 0.40
EPHX2 P34913 1/20 0.37
F13A1 P00488 1/20 0.36
PTGS1 P23219 1/20 0.36
PDE4A P27815 1/20 0.36
LMNA P02545 1/20 0.36
SLC6A6 P31641 1/20 0.36
CYP2C19 P33261 1/20 0.36
BLM P54132 1/20 0.36
MTNR1A P48039 4/20 0.35
MTNR1B P49286 4/20 0.35
NPSR1 Q6W5P4 1/20 0.34
GLP1R P43220 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Magnesium SCHEMBL31484747 0.98 KDM4E (0.54) KDM4EMAPK1HIF1APAOXTSHR
SCHEMBL28485860 0.98 KDM4E (0.54) KDM4EMAPK1HIF1APAOXTSHR
Calcium SCHEMBL2590651 0.98 KDM4E (0.54) KDM4EMAPK1HIF1APAOXTSHR
Water SCHEMBL926831 0.98 KDM4E (0.54) KDM4EMAPK1HIF1APAOXTSHR
SCHEMBL2780184 0.98 KDM4E (0.54) KDM4EMAPK1HIF1APAOXTSHR
Water SCHEMBL31512214 0.95 KDM4E (0.52) KDM4EMAPK1HIF1APAOXTSHR
Water SCHEMBL31512216 0.95 KDM4E (0.52) KDM4EMAPK1HIF1APAOXTSHR
Water SCHEMBL927462 0.95 KDM4E (0.52) KDM4EMAPK1HIF1APAOXTSHR
SCHEMBL17754088 0.86 KDM4E (0.65) KDM4EMAPK1HIF1APAOXTSHR
Acamprosate SCHEMBL41983 0.86 KDM4E (0.65) KDM4EMAPK1HIF1APAOXTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 372 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026087536-A1 METHODS OF USING HOMOTAURINE AND ANALOGS THEREOF FOR THE TREATMENT OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST INDUCED GASTROINTESTINAL SIDE EFFECTS UNIVERSITY OF TARTU (EE) 2026-04-30 WO claimed
US-12584924-B2 Compositions and methods for diagnosing and treating chronic kidney disease SOCIETE DES PRODUITS NESTLE S.A. (CH) 2026-03-24 US claimed
US-20260034171-A1 Composition for Improving Cognitive Function PERRY STEPHEN C (US) 2026-02-05 US claimed
WO-2025123045-A1 PREDICTIVE AND DIAGNOSTIC SCREENING METHODS FOR ENDOMETRIAL CANCER ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) 2025-06-12 WO claimed
CN-119504517-B Preparation method of magnesium acetyltaurate 浙江天启生化股份有限公司 2025-04-18 CN claimed
CN-119751315-A Method for preparing acetyltaurine calcium salt and other acetyltaurine salts 苏州满元生物科技有限公司 2025-04-04 CN claimed
WO-2025072741-A1 PRESERVATIVES FOR MOLECULAR SAMPLE ANALYSIS WITH SAMPLE COLLECTION DEVICES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2025-04-03 WO claimed
CN-119504517-A Preparation method of magnesium acetyltaurate 浙江天启生化股份有限公司 2025-02-25 CN claimed
CN-119431198-A Preparation method of magnesium acetyltaurate 苏州满元生物科技有限公司 2025-02-14 CN claimed
CN-119074711-A Application of N-lactoyl phenylalanine and N-acetyltaurine in preparation of multifunctional therapeutic drugs 广东药科大学 2024-12-06 CN claimed
US-20030229122-A1 Use of methylphenidate compounds to enhance memory SENTION, INC. 2003-12-11 US claimed
WO-2003060099-A2 METHODS AND APPARATUS FOR SPINNING SPIDER SILK PROTEIN NEXIA BIOTECHNOLOGIES, INC. (CA) 2003-07-24 WO claimed
EP-1315495-A2 USE OF THREO-METHYLPHENIDATE COMPOUNDS TO ENHANCE MEMORY Sention, Inc. (US) 2003-06-04 EP claimed
US-6524593-B1 Alleviate or improve various cosmetic conditions and dermatological disorders, skin, hair, nails TRISTRATA, INC. 2003-02-25 US claimed
US-20020132793-A1 Use of methylphenidate compounds to enhance memory SENTION INC. 2002-09-19 US claimed
US-20020103162-A1 Use of threo-methylphenidate compounds to enhance memory SENTION, INC. 2002-08-01 US claimed
WO-2002017920-A2 USE OF METHYLPHENIDATE COMPOUNDS TO ENHANCE MEMORY SENTION, INC (US) 2002-03-07 WO claimed
WO-2002017919-A2 USE OF THREO-METHYLPHENIDATE COMPOUNDS TO ENHANCE MEMORY SENTION, INC. (US) 2002-03-07 WO claimed
US-6159485-A COSMETICS; SKIN DISORDERS YUGENIC LIMITED PARTNERSHIP (US) 2000-12-12 US claimed
WO-2000040217-B1 TOPICAL COMPOSITION COMPRISING N-ACETYLALDOSAMINES OR N-ACETYLAMINO ACIDS YUGENIC LIMITED PARTNERSHIP (US) 2000-10-05 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034171-A1 Composition for Improving Cognitive Function PHOSPHO1, PSEN1, S100B KDM4E 3027/4885MAPK1 1966/4885HIF1A 3863/4885
US-20020132793-A1 Use of methylphenidate compounds to enhance memory PNMT, CHAT, SLC6A3 KDM4E 237/4885MAPK1 734/4885HIF1A 4006/4885
US-20020103162-A1 Use of threo-methylphenidate compounds to enhance memory SLC6A3, SLC6A2, PNMT KDM4E 437/4885MAPK1 450/4885HIF1A 4257/4885
US-12584924-B2 Compositions and methods for diagnosing and treating chronic kidney disease GLS, AADAT, FGF23 KDM4E 124/4885MAPK1 1697/4885HIF1A 37/4885
US-20030229122-A1 Use of methylphenidate compounds to enhance memory PNMT, GRIN3B, GRIN3A KDM4E 335/4885MAPK1 354/4885HIF1A 4061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.